Whole-exome Sequencing Reveals New Potential Susceptibility Genes for Japanese Familial Pancreatic Cancer. Issue 4 (18th April 2022)

• Record Type: Journal Article
• Authors: Takai, Erina; Nakamura, Hiromi; Chiku, Suenori; Kubo, Emi; Ohmoto, Akihiro; Totoki, Yasushi; Shibata, Tatsuhiro; Higuchi, Ryota; Yamamoto, Masakazu; Furuse, Junji; Shimizu, Kyoko; Takahashi, Hideaki; Morizane, Chigusa; Furukawa, Toru; Yachida, Shinichi
• Is Part Of: Annals of surgery. Volume 275:Issue 4(2022)
• Page Start: e652
• Page End: e658
• Publication Date: 2022-04-18
• Subjects: familial pancreatic cancer -- susceptibility genes -- whole-exome sequencing; Surgery -- Periodicals; 617.005
• DOI: 10.1097/SLA.0000000000004213
• Languages: English
• ISSNs: 0003-4932

Abstract

Abstract : Objective: The primary objective of this study was to identify novel genes that predispose people in the Japanese population to FPC. Summary of Background Data: Familial history of pancreatic cancer is an important risk factor but, to date, few genes predisposing individuals to increased risk of developing FPC have been identified. Methods: We performed whole-exome sequencing of germline DNA from 81 Japanese FPC patients. We also investigated somatic gene alterations in 21 matched tumor tissues through whole-exome sequencing and copy number analysis. Results: Our germline variants identified previously known FPC susceptibility genes such as ATM and BRCA2, and several novel tumor suppressor genes with potentially deleterious variants for FPC. Interestingly, somatic whole-exome analysis demonstrated that most tumor samples with suspicious loss of heterozygosity of candidate genes were KRAS wild-types, implying that these cases may not have required KRAS activation as a driver event for carcinogenesis. Conclusions: Our findings indicate that FPC patients harbor potentially deleterious causative germline variants in tumor suppressor genes, which are known to acquire somatic mutations in pancreatic cancer, and that somatic loss of heterozygosity of some FPC susceptibility genes may contribute to the development of FPC in the absence of somatic KRAS -activating mutation. Genetic testing for a wider variety of FPC-predisposition genes could provide better screening approach for high-risk groups of pancreatic cancer.